CAR T-cell therapy has revolutionized treatment for relapsed or refractory B cell lymphomas, particularly aggressive large B cell lymphoma (LBCL) such as diffuse large B cell lymphoma (DLBCL). Evidence available through 2026 shows that roughly 50–80% of appropriately selected patients respond, and about 30–40% achieve long-term remission or “functional cure,” depending on the CAR T product, lymphoma subtype, and line of therapy.
CAR T success rates for lymphoma in 2026
Most published success-rate data come from clinical trials and real-world studies of commercially manufactured CD19-directed CAR-T products, including axicabtagene ciloleucel, lisocabtagene maraleucel, and tisagenlecleucel. The most extensive evidence concerns large B-cell lymphoma, particularly DLBCL. Across pivotal trials, registries, and long-term follow-up studies, the following ranges provide a general picture of outcomes in eligible patients with aggressive B-cell lymphomas:
- Overall response rate (ORR): In many large B cell lymphoma series, about 60–80% of treated patients have a measurable response.
- Complete responses (CR): Roughly 40–60% achieve complete remission in key trials and registries, with some high risk subgroups showing slightly lower rates.
- Durable remission / progression free survival (PFS): A substantial proportion of patients who achieve a complete response remain progression free at 2 years and beyond; 2–5 year PFS rates around 30–40% and overall survival around 40–50% are reported in long term follow up of axicabtagene ciloleucel and similar products.
Lymphoma is not a single disease, and CAR-T outcomes should be interpreted according to the specific diagnosis.
Diffuse large B-cell lymphoma and other large B-cell lymphomas: These diseases have the largest body of clinical evidence. Many studies report overall response rates of approximately 60–80%, with complete responses in roughly 40–60% of treated patients. A proportion of patients remain in long-term remission.
Follicular lymphoma:
Clinical trials have reported high initial response and complete-response rates in selected patients with relapsed or refractory follicular lymphoma. However, these results should not be directly compared with DLBCL because follicular lymphoma has different disease biology and progression patterns.
Mantle cell lymphoma:
CAR-T can produce deep responses in patients whose disease has returned after several previous treatments. Nevertheless, the durability of response and the risk of relapse vary between patients.
Other non-Hodgkin lymphomas:
Evidence depends on the exact lymphoma subtype. Some forms of B-cell non-Hodgkin lymphoma may be considered for CAR-T treatment, while others have limited clinical evidence or may only be treated through particular protocols or clinical studies.
Therefore, a general “lymphoma success rate” can help patients understand the overall potential of CAR-T, but it cannot predict the result for an individual patient. Each application must be reviewed according to the precise diagnosis, previous treatments, disease status and available CAR-T program.
Why success rates vary between patients
Even with the same product, not every patient experiences the same benefit. Key factors influencing CAR T-cell success in lymphoma include:
Disease biology and timing of therapy
Patients treated earlier—such as those receiving CAR T as second line therapy after failing first line chemoimmunotherapy—tend to have better long term outcomes than those treated after multiple relapses. Very aggressive biology (for example double hit/high grade B cell lymphoma, early primary refractory disease, or Richter transformation) can reduce durability of remission even when the initial response looks promising.
Tumor burden and performance status
High tumor burden, bulky disease, or poor general condition at infusion are associated with both higher toxicity risk and lower chance of long lasting benefit. Patients who are fitter and have better disease control at the time of CAR T (sometimes achieved with bridging therapy) are more likely to enjoy durable remissions.
Type of CAR T product and protocol
Different CD19 CAR T products use distinct constructs and manufacturing methods, leading to variations in response depth, speed of response, and toxicity. Long term analyses of axicabtagene ciloleucel and lisocabtagene maraleucel, for example, show durable 5 year responses in a meaningful subset of patients, while ongoing studies continue to refine selection, dosing, and sequencing with other treatments.
Center experience and supportive care
CAR T should be delivered in experienced centers that can rapidly recognize and treat cytokine release syndrome (CRS), neurotoxicity, infections, and late complications. High volume centers with structured follow up pathways help reduce complications and support patients in maintaining their remission over the long term.
Publication date: December 2025
Updated: August 2026
Sources:
CAR T-cell therapy for B-cell lymphoma
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
CD19 CAR-T cell therapy for Relapsed or Refractory Diffuse Large B Cell Lymphoma; Why does it Fail?
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort
CAR T-cell therapy for B-cell lymphoma
Real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas
Links
Initiating your CAR-T medical inquiry >>
CAR-T testimonials
